LBO-002 Efruxifermin significantly reduced liver fibrosis in MASH patients with F2-F3 fibrosis, with sustained improvement in liver injury and resolution of steatohepatitis over 96 weeks (HARMONY phase 2b study)
Year: 2024
Type: conference-abstract
Source: Journal of Hepatology
Authors: Stephen A. Harrison, Juan P Frias, Guy Neff, Gary Abrams, Kathryn Jean Lucas, William Sanchez, Sudhanshu Gogia, Muhammad Y Sheikh, Cynthia Behling, Pierre Bedossa, Lan Shao, Doreen Chan, Erica Fong, Brittany de Temple, Matthew Minerva, Kimberly Barrett, Reshma Shringarpure, Erik Tillman, Tim Rolph, Andrew Cheng, Vlad Ratziu, Kitty Yale
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4399537162